<qa>  What antibody was introduced to the anti-PD-1 antibody Nivolumab?The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy AVD. 